Key facts
- This page summarizes Ellen Chiniara's Form 4 filing for Kymera Therapeutics, Inc. (KYMR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Jan 2025, 17:00.
Ellen Chiniara - 06 Jan 2025 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- KYMR
- Reported as of
- 06 Jan 2025
- Net transaction value
- -$130,645
- SEC form
- 4
- Accepted by SEC
- 06 Jan 2025, 17:00:04 UTC
- Prior SEC filing
- 04 Mar 2024
- Next SEC filing
- 13 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bruce Jacobs, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ellen Chiniara filed Form 4 for Kymera Therapeutics, Inc. (KYMR) on 06 Jan 2025.
Change
- Previous filing in this sequence was filed on 04 Mar 2024.
- Current net transaction value: -$130,645.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KYMR
transaction
Common Stock
Sale
- Transaction value
- $130,645
- Shares
- -3,129
- Change %
- -5.4%
- Price
- $41.75
- Shares after
- 54,826
- Date
- 06 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $41.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
This number includes 1,203 shares and 792 shares acquired under the Registrant's employee stock purchase plan on June 1, 2024 and December 1, 2024, respectively.